Scil Proteins establishes business development organisation in California

To be headed by Garry Merry

Scil Proteins, a German biotech specialist in the research, development and production of recombinant proteins, has established a business development organisation in California in response to increasing demand for the company’s protein production services in North America. The organisation, to be led by Garry Merry, will provide local business support for the company’s US and Canadian CMO customers.

Merry has a wealth of experience supporting the business development efforts of several small protein engineering, biopharmaceutical and drug discovery companies in North America, including Sloning Biotechnologies, Isogenica and TerraSep. He has also held senior executive positions at life science companies including Waters, Applied Biosystems and Qiagen.

‘A local presence to interface directly with our customers, collaborators and partners in North America is vital to ensure our continued success and the expansion of our business on a global basis,’ said Frank Ubags, chief operating officer of Scil Proteins. ‘With his background in protein engineering and separations, Garry is ideally positioned to help us achieve our growth objectives.’

Scil Proteins’ Affilin drug discovery platform, which is available for out-licensing to biotechnology and pharmaceutical companies, will continue to be supported out of the company’s headquarters in Halle, Germany. The corporate headquarters will also remain responsible for all other activities related to the company’s CMO business outside the US and Canada.

You may also like

Research & Development

ITM and Scil Proteins agree targeted radio conjugates partnership

German firms will develop targeted radio conjugates for imaging and therapy purposes, in a variety of indications
Ingredients

Scil Proteins receives EMA approval for commercial production of Reteplase

The recombinant protein will be produced in Halle, Germany
Research & Development

Scil Proteins signs partnership to research cancer therapies

Will work with Martin Luther University Halle-Wittenberg
Research & Development

Agilent introduces the Altura Line of Inert HPLC Columns for superior results in biotherapeutic testing

Helping biopharma labs reach new heights in analytical performance
Regulatory

Novartis secures FDA approval for Rhapsido, the first oral BTKi treatment for chronic spontaneous urticaria

Rhapsido (remibrutinib) offers a new targeted option for CSU patients, showing rapid symptom control and a favourable safety profile without lab monitoring, as Novartis expands its immunology portfolio
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Building resilient outsourcing strategies: safeguarding oncology research samples against disaster risk (part I)

With a focus on the evolving landscape of biorepositories, this article explores the critical importance of robust outsourcing strategies to protect oncology research samples from disaster risk. Lori A. Ball, Chief Executive Officer at Astoriom, reports
Research & Development

Veraxa and Secarna Pharmaceuticals partner to advance AOC therapies for immune diseases

The pair will develop next-generation antibody oligonucleotide conjugates (AOCs) with the aim of unlocking novel targeted therapies for the treatment of autoimmune and chronic immune diseases
Subscribe now